The FDA has issued an approvable letter to Wyeth for its antidepressant Pristiq. "The approvable letter is in line with Wyeth's expectations and we remain on track with our plans for Pristiq," says Joseph Mahady, President, Wyeth Pharmaceuticals, the Americas and Global Businesses. "We are working toward resolution of all outstanding issues at our manufacturing site in Guayama, Puerto Rico and have already made significant progress in meeting previously established commitments."

- here's the release [1] on Pristiq

Related Articles:
Wyeth expects provisional OK for Pristiq. Report [2]
Solvay expands development pact with Wyeth. Report [3]